{"product_id":"tesamorelin-10mg-vial","title":"Tesamorelin 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                       \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-end=\"3265\" data-start=\"2930\"\u003e\u003cstrong\u003eTesamorelin\u003c\/strong\u003e binds \u003cstrong data-end=\"2974\" data-start=\"2948\"\u003eGHRH receptors (GHRHR)\u003c\/strong\u003e on pituitary somatotrophs → \u003cstrong data-end=\"3023\" data-start=\"3003\"\u003eGs–cAMP–PKA–CREB\u003c\/strong\u003e signaling → \u003cstrong data-end=\"3059\" data-start=\"3036\"\u003eGH pulse generation\u003c\/strong\u003e. Peripheral \u003cstrong data-end=\"3078\" data-start=\"3072\"\u003eGH\u003c\/strong\u003e activates \u003cstrong data-end=\"3107\" data-start=\"3089\"\u003eGHR–JAK2–STAT5\u003c\/strong\u003e in liver and adipose, boosting \u003cstrong data-end=\"3148\" data-start=\"3139\"\u003eIGF-1\u003c\/strong\u003e and lipid-flux enzymes; \u003cstrong data-end=\"3189\" data-start=\"3173\"\u003esomatostatin\u003c\/strong\u003e and \u003cstrong data-end=\"3203\" data-start=\"3194\"\u003eIGF-1\u003c\/strong\u003e provide negative feedback that preserves physiologic rhythms.\u003c\/p\u003e\n\u003ch3 data-end=\"3294\" data-start=\"3267\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3719\" data-start=\"3296\"\u003e\n\u003cthead data-end=\"3338\" data-start=\"3296\"\u003e\n\u003ctr data-end=\"3338\" data-start=\"3296\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3306\" data-start=\"3296\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3327\" data-start=\"3306\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3338\" data-start=\"3327\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3719\" data-start=\"3353\"\u003e\n\u003ctr data-end=\"3450\" data-start=\"3353\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3371\" data-start=\"3353\"\u003eJAK2–STAT5 (GH)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3432\" data-start=\"3371\"\u003e↑ IGF-1, ↑ hormone-sensitive lipase, ↓ de novo lipogenesis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3450\" data-start=\"3432\"\u003eLiver, adipose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3533\" data-start=\"3451\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3475\" data-start=\"3451\"\u003ePI3K–Akt–mTOR (IGF-1)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3514\" data-start=\"3475\"\u003e↑ protein synthesis, ↑ fat-free mass\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3533\" data-start=\"3514\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3612\" data-start=\"3534\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3557\" data-start=\"3534\"\u003eAMPK\/PPAR cross-talk\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3603\" data-start=\"3557\"\u003e↓ hepatic steatosis, improved VLDL handling\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3612\" data-start=\"3603\"\u003eLiver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3719\" data-start=\"3613\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3639\" data-start=\"3613\"\u003eCNS neuroendocrine axes\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3691\" data-start=\"3639\"\u003eModulates sleep–metabolism–cognition via GH\/IGF-1\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3719\" data-start=\"3691\"\u003eHypothalamus\/hippocampus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3724\" data-start=\"3721\"\u003e\n\u003ch2 data-end=\"3748\" data-start=\"3726\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cp data-end=\"4267\" data-start=\"3750\"\u003e\u003cstrong data-end=\"3765\" data-start=\"3750\"\u003eAbsorption:\u003c\/strong\u003e Rapid after SC injection; \u003cstrong data-end=\"3805\" data-start=\"3792\"\u003eTmax ~1 h\u003c\/strong\u003e.\u003cbr data-end=\"3809\" data-start=\"3806\"\u003e\u003cstrong data-end=\"3832\" data-start=\"3809\"\u003eHalf-life (parent):\u003c\/strong\u003e \u003cstrong data-end=\"3843\" data-start=\"3833\"\u003e~1–2 h\u003c\/strong\u003e; pharmacodynamic effects persist via induced \u003cstrong data-end=\"3902\" data-start=\"3889\"\u003eGH pulses\u003c\/strong\u003e and \u003cstrong data-end=\"3916\" data-start=\"3907\"\u003eIGF-1\u003c\/strong\u003e (24–48 h).\u003cbr data-end=\"3930\" data-start=\"3927\"\u003e\u003cstrong data-end=\"3947\" data-start=\"3930\"\u003eDistribution:\u003c\/strong\u003e Primary site of action is pituitary; systemic effects mediated by GH\/IGF-1; minimal direct BBB penetration.\u003cbr data-end=\"4058\" data-start=\"4055\"\u003e\u003cstrong data-end=\"4072\" data-start=\"4058\"\u003eClearance:\u003c\/strong\u003e Peptidase degradation; no known CYP interactions.\u003cbr data-end=\"4125\" data-start=\"4122\"\u003e\u003cstrong data-end=\"4136\" data-start=\"4125\"\u003eDosing:\u003c\/strong\u003e Daily SC abdomen; rotate sites. \u003cstrong data-end=\"4188\" data-start=\"4169\"\u003eEGRIFTA SV 2 mg\u003c\/strong\u003e vs \u003cstrong data-end=\"4214\" data-start=\"4192\"\u003eEGRIFTA WR 1.28 mg\u003c\/strong\u003e—\u003cstrong data-end=\"4238\" data-start=\"4215\"\u003enot interchangeable\u003c\/strong\u003e. FDA Prescribing Information\u003c\/p\u003e\n\u003chr data-end=\"4272\" data-start=\"4269\"\u003e\n\u003ch2 data-end=\"4319\" data-start=\"4274\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4377\" data-start=\"4321\"\u003e4.1 HIV-Associated Lipodystrophy (core indication)\u003c\/h3\u003e\n\u003cp data-end=\"4595\" data-start=\"4378\"\u003eMultiple RCTs demonstrate \u003cstrong data-end=\"4438\" data-start=\"4404\"\u003eclinically meaningful VAT loss\u003c\/strong\u003e, \u003cstrong data-end=\"4466\" data-start=\"4440\"\u003etriglyceride reduction\u003c\/strong\u003e, and improved adipokines over \u003cstrong data-end=\"4512\" data-start=\"4497\"\u003e26–52 weeks\u003c\/strong\u003e, with \u003cstrong data-end=\"4543\" data-start=\"4519\"\u003eVAT rebound off-drug\u003c\/strong\u003e and re-response upon \u003cstrong data-end=\"4581\" data-start=\"4565\"\u003ere-treatment\u003c\/strong\u003e. \u003cem data-end=\"4595\" data-start=\"4583\"\u003eNEJM; AIDS\u003c\/em\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"4638\" data-start=\"4597\"\u003e4.2 Hepatic Steatosis \/ MASH in HIV\u003c\/h3\u003e\n\u003cp data-end=\"4866\" data-start=\"4639\"\u003e12-month randomized data show \u003cstrong data-end=\"4692\" data-start=\"4669\"\u003ereduced hepatic fat\u003c\/strong\u003e and \u003cstrong data-end=\"4732\" data-start=\"4697\"\u003elower fibrosis-progression risk\u003c\/strong\u003e; mechanisms likely include \u003cstrong data-end=\"4787\" data-start=\"4760\"\u003eGH-dependent lipid flux\u003c\/strong\u003e and \u003cstrong data-end=\"4825\" data-start=\"4792\"\u003eIGF-1 anti-fibrotic signaling\u003c\/strong\u003e. \u003cem data-end=\"4866\" data-start=\"4827\"\u003eLancet HIV; Hepatology Communications\u003c\/em\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"4893\" data-start=\"4868\"\u003e4.3 Cognitive Aging\u003c\/h3\u003e\n\u003cp data-end=\"5149\" data-start=\"4894\"\u003eA 20-week placebo-controlled trial in \u003cstrong data-end=\"4975\" data-start=\"4932\"\u003ehealthy older adults and those with MCI\u003c\/strong\u003e reported \u003cstrong data-end=\"5027\" data-start=\"4985\"\u003eimproved executive function and memory\u003c\/strong\u003e with tesamorelin-class GHRH analog therapy, correlating with \u003cstrong data-end=\"5098\" data-start=\"5089\"\u003eIGF-1\u003c\/strong\u003e increases. \u003cem data-end=\"5149\" data-start=\"5110\"\u003eArchives of Neurology; JAMA Neurology\u003c\/em\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5181\" data-start=\"5151\"\u003e4.4 Cardiometabolic Risk\u003c\/h3\u003e\n\u003cp data-end=\"5371\" data-start=\"5182\"\u003eVAT responders show \u003cstrong data-end=\"5226\" data-start=\"5202\"\u003ehigher HDL, lower TG\u003c\/strong\u003e, and \u003cstrong data-end=\"5264\" data-start=\"5232\"\u003ereduced inflammatory markers\u003c\/strong\u003e; risk modeling suggests \u003cstrong data-end=\"5331\" data-start=\"5289\"\u003efavorable shifts in 10-year ASCVD risk\u003c\/strong\u003e. \u003cem data-end=\"5371\" data-start=\"5333\"\u003eJCEM; Journal of Clinical Lipidology\u003c\/em\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5419\" data-start=\"5373\"\u003e4.5 Body Composition \u0026amp; Physical Function\u003c\/h3\u003e\n\u003cp data-end=\"5588\" data-start=\"5420\"\u003eDXA\/CT sub-studies indicate \u003cstrong data-end=\"5482\" data-start=\"5448\"\u003epreferential visceral-fat loss\u003c\/strong\u003e with \u003cstrong data-end=\"5531\" data-start=\"5488\"\u003emaintenance or slight gain of lean mass\u003c\/strong\u003e and improved abdominal comfort\/mobility. \u003cem data-end=\"5588\" data-start=\"5573\"\u003eObesity; AIDS\u003c\/em\u003e\u003c\/p\u003e\n\u003chr data-end=\"5593\" data-start=\"5590\"\u003e\n\u003ch2 data-end=\"5628\" data-start=\"5595\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6121\" data-start=\"5630\"\u003e\n\u003cthead data-end=\"5668\" data-start=\"5630\"\u003e\n\u003ctr data-end=\"5668\" data-start=\"5630\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5638\" data-start=\"5630\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5650\" data-start=\"5638\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5668\" data-start=\"5650\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6121\" data-start=\"5683\"\u003e\n\u003ctr data-end=\"5811\" data-start=\"5683\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5704\" data-start=\"5683\"\u003e\u003cstrong data-end=\"5703\" data-start=\"5685\"\u003eHIV-NAFLD\/MASH\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5759\" data-start=\"5704\"\u003eVAT–liver axis; anti-steatotic\/anti-fibrotic signals\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5811\" data-start=\"5759\"\u003ePhase 2–3 translational work; label not expanded\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5928\" data-start=\"5812\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5837\" data-start=\"5812\"\u003e\u003cstrong data-end=\"5836\" data-start=\"5814\"\u003eSarcopenic obesity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5888\" data-start=\"5837\"\u003eIGF-1–mediated anabolism with selective VAT loss\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5928\" data-start=\"5888\"\u003eEarly feasibility; no pivotal trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6035\" data-start=\"5929\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5955\" data-start=\"5929\"\u003e\u003cstrong data-end=\"5954\" data-start=\"5931\"\u003eCognitive aging\/MCI\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5993\" data-start=\"5955\"\u003eGHRH→GH→IGF-1 neurotrophic pathways\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6035\" data-start=\"5993\"\u003eSmall RCT signal; larger trials needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6121\" data-start=\"6036\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6060\" data-start=\"6036\"\u003e\u003cstrong data-end=\"6059\" data-start=\"6038\"\u003eNAFLD without HIV\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6095\" data-start=\"6060\"\u003eGH-deficiency phenotype in NAFLD\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6121\" data-start=\"6095\"\u003ePilot studies proposed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6126\" data-start=\"6123\"\u003e\n\u003ch2 data-end=\"6157\" data-start=\"6128\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cp data-end=\"6698\" data-start=\"6159\"\u003e\u003cstrong data-end=\"6170\" data-start=\"6159\"\u003eCommon:\u003c\/strong\u003e Injection-site reactions, \u003cstrong data-end=\"6206\" data-start=\"6197\"\u003eedema\u003c\/strong\u003e, \u003cstrong data-end=\"6230\" data-start=\"6208\"\u003earthralgia\/myalgia\u003c\/strong\u003e, \u003cstrong data-end=\"6275\" data-start=\"6232\"\u003eparesthesia\/carpal-tunnel-like symptoms\u003c\/strong\u003e (fluid retention).\u003cbr data-end=\"6297\" data-start=\"6294\"\u003e\u003cstrong data-end=\"6311\" data-start=\"6297\"\u003eEndocrine:\u003c\/strong\u003e \u003cstrong data-end=\"6331\" data-start=\"6312\"\u003eIGF-1 elevation\u003c\/strong\u003e—monitor; \u003cstrong data-end=\"6364\" data-start=\"6341\"\u003eglucose intolerance\u003c\/strong\u003e can emerge (check FPG\/HbA1c; adjust antidiabetics).\u003cbr data-end=\"6419\" data-start=\"6416\"\u003e\u003cstrong data-end=\"6441\" data-start=\"6419\"\u003eContraindications:\u003c\/strong\u003e \u003cstrong data-end=\"6455\" data-start=\"6442\"\u003ePregnancy\u003c\/strong\u003e, \u003cstrong data-end=\"6478\" data-start=\"6457\"\u003eactive malignancy\u003c\/strong\u003e, hypersensitivity (e.g., mannitol).\u003cbr data-end=\"6517\" data-start=\"6514\"\u003e\u003cstrong data-end=\"6530\" data-start=\"6517\"\u003eOncology:\u003c\/strong\u003e Theoretical \u003cstrong data-end=\"6574\" data-start=\"6543\"\u003eIGF-1-driven mitogenic risk\u003c\/strong\u003e; discontinue if malignancy occurs.\u003cbr data-end=\"6612\" data-start=\"6609\"\u003e\u003cstrong data-end=\"6631\" data-start=\"6612\"\u003eOphthalmic\/OSA:\u003c\/strong\u003e Fluid shifts may unmask\/worsen \u003cstrong data-end=\"6678\" data-start=\"6663\"\u003eretinopathy\u003c\/strong\u003e or \u003cstrong data-end=\"6697\" data-start=\"6682\"\u003esleep apnea\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp data-end=\"6729\" data-start=\"6700\"\u003e\u003cstrong data-end=\"6729\" data-start=\"6700\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7214\" data-start=\"6731\"\u003e\n\u003cthead data-end=\"6788\" data-start=\"6731\"\u003e\n\u003ctr data-end=\"6788\" data-start=\"6731\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6741\" data-start=\"6731\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6769\" data-start=\"6741\"\u003eTesamorelin (GHRH analog)\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6788\" data-start=\"6769\"\u003eSomatropin (GH)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7214\" data-start=\"6803\"\u003e\n\u003ctr data-end=\"6898\" data-start=\"6803\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6817\" data-start=\"6803\"\u003eGH dynamics\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6856\" data-start=\"6817\"\u003e\u003cstrong data-end=\"6855\" data-start=\"6819\"\u003ePhysiologic pulses via pituitary\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6898\" data-start=\"6856\"\u003e\u003cstrong data-end=\"6896\" data-start=\"6858\"\u003eNon-physiologic exogenous exposure\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6962\" data-start=\"6899\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6915\" data-start=\"6899\"\u003eIGF-1 control\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6938\" data-start=\"6915\"\u003e\u003cstrong data-end=\"6937\" data-start=\"6917\"\u003eFeedback-limited\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6962\" data-start=\"6938\"\u003eDirectly dose-driven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7048\" data-start=\"6963\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6982\" data-start=\"6963\"\u003eEdema\/arthralgia\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7009\" data-start=\"6982\"\u003eModerate, dose-dependent\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7048\" data-start=\"7009\"\u003eModerate–higher at equipotent IGF-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7132\" data-start=\"7049\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7066\" data-start=\"7049\"\u003eGlucose impact\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7103\" data-start=\"7066\"\u003eNeutral → mild worsening (monitor)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7132\" data-start=\"7103\"\u003eSimilar or slightly worse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7214\" data-start=\"7133\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7152\" data-start=\"7133\"\u003eEvidence for VAT\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7187\" data-start=\"7152\"\u003eRobust RCTs in HIV lipodystrophy\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7214\" data-start=\"7187\"\u003eMixed in non-GHD adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7219\" data-start=\"7216\"\u003e\n\u003ch2 data-end=\"7247\" data-start=\"7221\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cp data-end=\"7600\" data-start=\"7249\"\u003e\u003cstrong data-end=\"7266\" data-start=\"7249\"\u003eApproved use:\u003c\/strong\u003e Reduction of excess abdominal fat in \u003cstrong data-end=\"7336\" data-start=\"7304\"\u003eHIV-associated lipodystrophy\u003c\/strong\u003e.\u003cbr data-end=\"7340\" data-start=\"7337\"\u003e\u003cstrong data-end=\"7362\" data-start=\"7340\"\u003eFormulations (US):\u003c\/strong\u003e \u003cstrong data-end=\"7382\" data-start=\"7363\"\u003eEGRIFTA SV 2 mg\u003c\/strong\u003e and \u003cstrong data-end=\"7409\" data-start=\"7387\"\u003eEGRIFTA WR 1.28 mg\u003c\/strong\u003e once daily SC; \u003cstrong data-end=\"7448\" data-start=\"7425\"\u003enot interchangeable\u003c\/strong\u003e.\u003cbr data-end=\"7452\" data-start=\"7449\"\u003e\u003cstrong data-end=\"7475\" data-start=\"7452\"\u003eLimitations of use:\u003c\/strong\u003e Not indicated for general weight loss; continue therapy \u003cstrong data-end=\"7571\" data-start=\"7532\"\u003eonly if VAT reduction is documented\u003c\/strong\u003e. FDA Prescribing Information\u003c\/p\u003e\n\u003chr data-end=\"7605\" data-start=\"7602\"\u003e\n\u003ch2 data-end=\"7630\" data-start=\"7607\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"8124\" data-start=\"7632\"\u003e\n\u003cli data-end=\"7749\" data-start=\"7632\"\u003e\n\u003cp data-end=\"7749\" data-start=\"7634\"\u003e\u003cstrong data-end=\"7660\" data-start=\"7634\"\u003eMetabolic phenotyping:\u003c\/strong\u003e Trials in \u003cstrong data-end=\"7689\" data-start=\"7671\"\u003eHIV-NAFLD\/MASH\u003c\/strong\u003e and \u003cstrong data-end=\"7716\" data-start=\"7694\"\u003esarcopenic obesity\u003c\/strong\u003e with imaging\/biopsy endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7912\" data-start=\"7750\"\u003e\n\u003cp data-end=\"7912\" data-start=\"7752\"\u003e\u003cstrong data-end=\"7776\" data-start=\"7752\"\u003eCombination therapy:\u003c\/strong\u003e Pairing with \u003cstrong data-end=\"7812\" data-start=\"7790\"\u003eGLP-1\/GIP agonists\u003c\/strong\u003e or \u003cstrong data-end=\"7836\" data-start=\"7816\"\u003eSGLT2 inhibitors\u003c\/strong\u003e to amplify hepatic and cardiometabolic outcomes while managing glycaemia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8001\" data-start=\"7913\"\u003e\n\u003cp data-end=\"8001\" data-start=\"7915\"\u003e\u003cstrong data-end=\"7936\" data-start=\"7915\"\u003ePrecision dosing:\u003c\/strong\u003e \u003cstrong data-end=\"7967\" data-start=\"7937\"\u003eIGF-1 SDS-guided titration\u003c\/strong\u003e to balance efficacy and safety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8124\" data-start=\"8002\"\u003e\n\u003cp data-end=\"8124\" data-start=\"8004\"\u003e\u003cstrong data-end=\"8028\" data-start=\"8004\"\u003eFormulation science:\u003c\/strong\u003e Long-acting depot or alternative delivery (e.g., transdermal, intranasal) to improve adherence.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8129\" data-start=\"8126\"\u003e\n\u003ch3 data-end=\"8154\" data-start=\"8131\"\u003eSelected References\u003c\/h3\u003e\n\u003cp data-end=\"9060\" data-start=\"8156\"\u003eFalutz J. et al. Randomized trials of tesamorelin in HIV lipodystrophy—VAT reduction and metabolic effects. \u003cem data-end=\"8297\" data-start=\"8264\"\u003eNew England Journal of Medicine\u003c\/em\u003e; \u003cem data-end=\"8305\" data-start=\"8299\"\u003eAIDS\u003c\/em\u003e.\u003cbr data-end=\"8309\" data-start=\"8306\"\u003eStanley T.L. et al. Tesamorelin for HIV-associated NAFLD—reduced liver fat and fibrosis-progression risk. \u003cem data-end=\"8427\" data-start=\"8415\"\u003eLancet HIV\u003c\/em\u003e; \u003cem data-end=\"8456\" data-start=\"8429\"\u003eHepatology Communications\u003c\/em\u003e.\u003cbr data-end=\"8460\" data-start=\"8457\"\u003eEngelson E.S. et al. Body-image and QoL outcomes with tesamorelin. \u003cem data-end=\"8541\" data-start=\"8527\"\u003eHIV Medicine\u003c\/em\u003e; \u003cem data-end=\"8554\" data-start=\"8543\"\u003eAIDS Care\u003c\/em\u003e.\u003cbr data-end=\"8558\" data-start=\"8555\"\u003eJohnen H. et al. Adipokines, triglycerides, and inflammatory markers in VAT responders. \u003cem data-end=\"8694\" data-start=\"8646\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/em\u003e.\u003cbr data-end=\"8698\" data-start=\"8695\"\u003eBaker L.D. et al. GHRH analog (tesamorelin) improves cognition in older adults with\/without MCI. \u003cem data-end=\"8818\" data-start=\"8795\"\u003eArchives of Neurology\u003c\/em\u003e; \u003cem data-end=\"8836\" data-start=\"8820\"\u003eJAMA Neurology\u003c\/em\u003e.\u003cbr data-end=\"8840\" data-start=\"8837\"\u003eGrunfeld C. et al. Glycaemic safety and IGF-1 monitoring across tesamorelin RCTs. \u003cem data-end=\"8937\" data-start=\"8922\"\u003eDiabetes Care\u003c\/em\u003e; \u003cem data-end=\"8945\" data-start=\"8939\"\u003eAIDS\u003c\/em\u003e.\u003cbr data-end=\"8949\" data-start=\"8946\"\u003eTheratechnologies. \u003cstrong data-end=\"9009\" data-start=\"8968\"\u003eEGRIFTA SV\/WR Prescribing Information\u003c\/strong\u003e—indication, dosing, contraindications, monitoring.\u003c\/p\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684855378258,"sku":null,"price":60.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/tesamorelin_10mg.png?v=1770834874","url":"https:\/\/sciencepeptideslab.com\/products\/tesamorelin-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}